Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 3
1984 2
1985 3
1986 1
1987 1
1988 1
1989 2
1992 1
1993 1
1994 1
1995 2
1996 3
1998 1
1999 3
2000 7
2001 2
2002 5
2003 4
2004 7
2005 5
2006 16
2007 9
2008 8
2009 9
2010 12
2011 11
2012 15
2013 11
2014 10
2015 14
2016 24
2017 12
2018 11
2019 14
2020 32
2021 26
2022 21
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
Bhagat A, Kleinerman ES. Bhagat A, et al. Adv Exp Med Biol. 2020;1257:181-192. doi: 10.1007/978-3-030-43032-0_15. Adv Exp Med Biol. 2020. PMID: 32483740 Review.
This chapter summarizes the identified mechanisms that may play a role in anthracycline-induced cardiotoxicity. We will also summarize the types of cardiomyopathies that have been described in survivors treated with doxorubicin and the current recommendations for mo …
This chapter summarizes the identified mechanisms that may play a role in anthracycline-induced cardiotoxicity. We will also summariz …
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity.
Wu L, Wang L, Du Y, Zhang Y, Ren J. Wu L, et al. Trends Pharmacol Sci. 2023 Jan;44(1):34-49. doi: 10.1016/j.tips.2022.10.003. Epub 2022 Nov 14. Trends Pharmacol Sci. 2023. PMID: 36396497 Review.
Importantly, recent advances have unveiled a major role for defective mitochondrial quality control in the etiology of DOX cardiomyopathy. Moreover, specific interventions targeting these quality control mechanisms to preserve mitochondrial function ha …
Importantly, recent advances have unveiled a major role for defective mitochondrial quality control in the etiology of DOX cardiom …
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
de Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, Mavinkurve-Groothuis AM, Kremer LC, van Dalen EC. de Baat EC, et al. Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2. Cochrane Database Syst Rev. 2022. PMID: 36162822 Free PMC article. Review.
OBJECTIVES: To assess the efficacy of dexrazoxane to prevent or reduce cardiotoxicity and determine possible effects of dexrazoxane on antitumour efficacy, quality of life and toxicities other than cardiac damage in adults and children with cancer receiving anthracyclin …
OBJECTIVES: To assess the efficacy of dexrazoxane to prevent or reduce cardiotoxicity and determine possible effects of dexrazoxane o …
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
Abdel-Qadir H, Ong G, Fazelzad R, Amir E, Lee DS, Thavendiranathan P, Tomlinson G. Abdel-Qadir H, et al. Ann Oncol. 2017 Mar 1;28(3):628-633. doi: 10.1093/annonc/mdw671. Ann Oncol. 2017. PMID: 28028033 Free article.
BACKGROUND: The relative efficacy of interventions for primary prevention of anthracycline-associated cardiotoxicity is unknown. METHODS: We conducted a systematic review of randomized controlled trials for primary prevention of anthracycline …
BACKGROUND: The relative efficacy of interventions for primary prevention of anthracycline-associated cardiotoxicity is …
Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
Sabatino J, De Rosa S, Tammè L, Iaconetti C, Sorrentino S, Polimeni A, Mignogna C, Amorosi A, Spaccarotella C, Yasuda M, Indolfi C. Sabatino J, et al. Cardiovasc Diabetol. 2020 May 15;19(1):66. doi: 10.1186/s12933-020-01040-5. Cardiovasc Diabetol. 2020. PMID: 32414364 Free PMC article.
These beneficial effect on HF were apparently independent from glucose control. However, no mechanistic in vivo studies are available to explain these results, yet. We aimed to determine the effect of empagliflozin on left ventricular (LV) function in a mouse model of doxo …
These beneficial effect on HF were apparently independent from glucose control. However, no mechanistic in vivo studies are available …
Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy.
Dhingra R, Rabinovich-Nikitin I, Rothman S, Guberman M, Gang H, Margulets V, Jassal DS, Alagarsamy KN, Dhingra S, Valenzuela Ripoll C, Billia F, Diwan A, Javaheri A, Kirshenbaum LA. Dhingra R, et al. Circulation. 2022 Sep 20;146(12):934-954. doi: 10.1161/CIRCULATIONAHA.121.058411. Epub 2022 Aug 19. Circulation. 2022. PMID: 35983756 Free PMC article.
Here, we investigate alterations in TNFalpha-TRAF2-NF-kappaB signaling in the pathogenesis of DOX cardiotoxicity. METHODS: Using a combination of in vivo (4 weekly injections of DOX 5 mg.kg(-1).wk(-1)) in C57/BL6J mice and in vitro approaches (rat, mouse, and human inducib …
Here, we investigate alterations in TNFalpha-TRAF2-NF-kappaB signaling in the pathogenesis of DOX cardiotoxicity. METHODS: Using a co …
Mitochondrial Sirtuin-3 (SIRT3) Prevents Doxorubicin-Induced Dilated Cardiomyopathy by Modulating Protein Acetylation and Oxidative Stress.
Tomczyk MM, Cheung KG, Xiang B, Tamanna N, Fonseca Teixeira AL, Agarwal P, Kereliuk SM, Spicer V, Lin L, Treberg J, Tong Q, Dolinsky VW. Tomczyk MM, et al. Circ Heart Fail. 2022 May;15(5):e008547. doi: 10.1161/CIRCHEARTFAILURE.121.008547. Epub 2022 Apr 14. Circ Heart Fail. 2022. PMID: 35418250 Free PMC article.
Here, we hypothesize that SIRT3 expression can attenuate doxorubicin induced dilated cardiomyopathy in vivo by preventing the acetylation of mitochondrial proteins. ...Increased M1-SIRT3 expression in vivo prevented doxorubicin-induced cardiac dysfunction, su …
Here, we hypothesize that SIRT3 expression can attenuate doxorubicin induced dilated cardiomyopathy in vivo by preventing the …
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG. Gongora CA, et al. JACC Heart Fail. 2022 Aug;10(8):559-567. doi: 10.1016/j.jchf.2022.03.006. Epub 2022 Jun 8. JACC Heart Fail. 2022. PMID: 35902159 Free PMC article.
METHODS: This study identified 3,033 patients with diabetes mellitus (DM) and cancer who were treated with anthracyclines. Cases were patients with cancer and DM who were on SGLT2 inhibitor therapy during anthracycline treatment (n = 32). Control parti …
METHODS: This study identified 3,033 patients with diabetes mellitus (DM) and cancer who were treated with anthracyclines. Cas …
Self-Maintenance of Cardiac Resident Reparative Macrophages Attenuates Doxorubicin-Induced Cardiomyopathy Through the SR-A1-c-Myc Axis.
Zhang H, Xu A, Sun X, Yang Y, Zhang L, Bai H, Ben J, Zhu X, Li X, Yang Q, Wang Z, Wu W, Yang D, Zhang Y, Xu Y, Chen Q. Zhang H, et al. Circ Res. 2020 Aug 14;127(5):610-627. doi: 10.1161/CIRCRESAHA.119.316428. Epub 2020 May 29. Circ Res. 2020. PMID: 32466726 Free article.
RATIONALE: Doxorubicin-induced cardiomyopathy (DiCM) is a primary cause of heart failure and mortality in cancer patients, in which macrophage-orchestrated inflammation serves as an essential pathological mechanism. ...OBJECTIVE: Uncovering the origins, phenotypes, and fun …
RATIONALE: Doxorubicin-induced cardiomyopathy (DiCM) is a primary cause of heart failure and mortality in cancer patients, in which m …
Three cases of late-onset anthracycline-related cardiomyopathy due to chemotherapies for hematological malignancy.
Kawano N, Kawano S, Yoshida S, Kuriyama T, Tochigi T, Nakaike T, Shimokawa T, Yamashita K, Ochiai H, Shimoda K, Mashiba K, Kikuchi I. Kawano N, et al. J Echocardiogr. 2021 Mar;19(1):45-52. doi: 10.1007/s12574-020-00484-8. Epub 2020 Aug 6. J Echocardiogr. 2021. PMID: 32761519
METHODS: We analyzed three cases of anthracycline-related cardiomyopathy among 996 patients with either acute myelogenous leukemia (285), acute lymphoblastic leukemia (37), or malignant lymphoma (674) at our hospital during the period from 2006 to 2016. ...CO …
METHODS: We analyzed three cases of anthracycline-related cardiomyopathy among 996 patients with either acute myelogeno …
286 results